How CAR T-Cell Therapy Has Evolved in Hematologic Malignancies
Frederick L. Locke, MD, discusses how chimeric antigen receptor (CAR) T-cell therapies have evolved over the last 30 years of research in the field of hematologic malignancies.
Frederick L. Locke, MD, medical director and research director of the Immune Cell Therapy Program and the co-program leader of the Immunology Program, vice chair of the Blood and Marrow Transplant and Cellular Immunotherapy program at Moffitt Cancer Center, discusses how chimeric antigen receptor (CAR) T-cell therapies have evolved over the last 30 years of research in the field of hematologic malignancies.
Early work with CAR T cells demonstrated their capabilities in animal models, but it wasn’t until second-generation CAR T cells were introduced that the real benefit for patients was seen in larger, multicenter trials, such as the ZUMA-1 trial that led to the approval of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with large B-cell lymphomas, Locke said.
Investigational FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer
October 28th 2024TYRA-300 showed promising safety and preliminary antitumor activity in FGFR3-altered metastatic urothelial cancer, with a 54.5% partial response rate and 100% disease control in the SURF301 trial.
Read More
